Sobi showcases new data across rare inflammatory conditions at ACR 2025
Comunicato Precedente
Comunicato Successivo
Summary of full Sobi data to be presented at ACR 2025:
Date: Tuesday 28 October
Session time: 1:00 PM - 2:30 PM CT
Presentation time: 1:30 PM - 1:45 PM CT
Date: Tuesday 28 October
Session time: 1:00 PM - 2:30 PM CT
Presentation time: 1:45 PM - 2:00 PM CT
Date: Monday 27 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Tuesday 28 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Tuesday 28 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Monday 27 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Tuesday 28 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Monday 27 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Tuesday 28 October
Presentation time: 10:30 AM - 12:30 PM CT
Date: Sunday 26 October
Session time: 1:00 PM - 2:30 PM CT
Presentation time: 1:45 PM - 2:00 PM CT
Date: Monday 27 October
Session time: 1:00 PM - 2:30 PM CT
Presentation time: 1:45 PM - 2:00 PM CT
Date: Tuesday 28 October
Presentation Time: 10:30 AM - 12:30 PM CT
Assistant Professor of Medicine, Mayo Clinic Rochester
Date: Sunday 26 October
Session time: 1:00 PM - 2:30 PM CT
Presentation time: 1:00 PM - 1:15 PM CT
Date: Wednesday 29 October
Session time: 11:30 AM - 1:00 PM CT
Presentation time: 11:30 AM - 11:45 AM CT
Date: Sunday 26 October
Presentation time: 10:30 AM - 12:30 PM CT
About NASP
NASP is a novel investigational medicine designed to reduce serum uric acid (sUA) levels in people living with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout.
About Uncontrolled Gout
Gout is the most common form of inflammatory arthritis with more than 8.3 million people in the United States having been diagnosed. Gout is caused by high levels of uric acid in the body that accumulate around the joints and other tissues and can result in flares that cause intense pain. Approximately 200,000 people in the United States suffer from uncontrolled gout, with serum uric acid (sUA) levels above 6 mg/dL despite treatment with oral urate lowering therapies. This leads to debilitating flares and tophi. Elevated sUA levels have also been associated with diseases of the heart, vascular system, metabolism, kidney and joints.
About Gamifant (emapalumab-lzsg)
Gamifant is the only approved anti-interferon gamma (IFNy) monoclonal antibody. Gamifant works by binding to and neutralizing interferon gamma (IFNy). When interferon gamma (IFNy) is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour.
Gamifant is approved in the US for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
About macrophage activation syndrome (MAS)
Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory nature with common clinical manifestations such as daily spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinaemia, possibly progressing to multiple organ failure and death. MAS is classified as a secondary form of haemophagocytic lymphohistiocytosis (HLH).
About Vonjo (pacritinib)
Vonjo is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
About VEXAS
VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-showcases-new-data-across-rare-inflammatory-conditions-at-acr-2025,c4256001
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/sobi-showcases-new-data-across-rare-inflammatory-conditions-at-acr-2025-302593848.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
